MX368897B - Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos. - Google Patents

Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.

Info

Publication number
MX368897B
MX368897B MX2017014127A MX2017014127A MX368897B MX 368897 B MX368897 B MX 368897B MX 2017014127 A MX2017014127 A MX 2017014127A MX 2017014127 A MX2017014127 A MX 2017014127A MX 368897 B MX368897 B MX 368897B
Authority
MX
Mexico
Prior art keywords
conjugates
gbs
methods
group
protein
Prior art date
Application number
MX2017014127A
Other languages
English (en)
Other versions
MX2017014127A (es
Inventor
Kathrin Ute Jansen
Annaliesa Sybil Anderson
Mark Edward Ruppen
Lakshmi Khandke
Jianxin Gu
Robert G K Donald
Rajesh Kumar Kainthan
Jin-Hwan Kim
Krishna Prasad Avvari
Singh Bhupender Bhalla Amardeep
Liberator Paul
Lea Scully Ingrid
Singh Suddham
Xudong Yang Cindy
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2017014127A publication Critical patent/MX2017014127A/es
Publication of MX368897B publication Critical patent/MX368897B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Sustainable Development (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a conjugados inmunógenos proteína-polisacárido que comprenden un polisacárido capsular (CP) de Streptococcus agalactiae, denominado comúnmente estreptococo grupo B (GBS), y una proteína portadora, en donde el CP se selecciona del grupo que consiste en los serotipos la, Ib, II, III, IV, V, VI, VII, VIII y IX, y en donde el CP tiene un nivel de ácido siálico mayor de alrededor de 60 %; la invención también se refiere a métodos para obtener los conjugados y las composiciones inmunógenas que comprenden los conjugados; la invención también se refiere a composiciones inmunógenas que comprenden conjugados proteína-polisacárido, en donde los conjugados comprenden un CP de GBS serotipo IV y al menos un serotipo adicional; asimismo, la invención se refiere a métodos para inducir una respuesta inmunitaria en sujetos contra GBS y/o para reducir o prevenir la enfermedad por GBS invasivo en sujetos usando las composiciones descritas en la presente; los anticuerpos resultantes se pueden usar para tratar o prevenir la infección por GBS mediante inmunoterapia pasiva.
MX2017014127A 2015-05-04 2016-04-29 Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos. MX368897B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562156500P 2015-05-04 2015-05-04
US201562237820P 2015-10-06 2015-10-06
US201562237813P 2015-10-06 2015-10-06
US201662319539P 2016-04-07 2016-04-07
PCT/IB2016/052455 WO2016178123A1 (en) 2015-05-04 2016-04-29 Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

Publications (2)

Publication Number Publication Date
MX2017014127A MX2017014127A (es) 2018-03-01
MX368897B true MX368897B (es) 2019-10-21

Family

ID=55967339

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014127A MX368897B (es) 2015-05-04 2016-04-29 Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.

Country Status (21)

Country Link
US (4) US10226525B2 (es)
EP (1) EP3292146A1 (es)
JP (3) JP6948951B2 (es)
KR (2) KR102143534B1 (es)
CN (2) CN107624070A (es)
AU (2) AU2016258284C1 (es)
BR (1) BR112017022776A2 (es)
CA (1) CA2928602A1 (es)
CO (1) CO2017011245A2 (es)
IL (2) IL255106B2 (es)
MX (1) MX368897B (es)
MY (1) MY182282A (es)
NZ (1) NZ736238A (es)
PE (2) PE20180172A1 (es)
PH (1) PH12017501898A1 (es)
RU (1) RU2692923C2 (es)
SA (1) SA517390274B1 (es)
SG (2) SG10202101887WA (es)
TW (2) TWI807252B (es)
WO (1) WO2016178123A1 (es)
ZA (1) ZA201807203B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR20180099912A (ko) * 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015110940A2 (en) * 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
PE20180172A1 (es) 2015-05-04 2018-01-22 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
US10751402B2 (en) * 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CN108144052A (zh) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 肺炎链球菌多糖-蛋白质缀合物及其制取方法和用途
US20190343951A1 (en) * 2017-01-13 2019-11-14 National Research Council Of Canada Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines
CN116870144A (zh) 2017-01-31 2023-10-13 默沙东有限责任公司 制备多糖-蛋白缀合物的方法
KR20190119108A (ko) * 2017-02-24 2019-10-21 머크 샤프 앤드 돔 코포레이션 폐렴구균 접합체 백신 제제
CN110337307A (zh) 2017-02-24 2019-10-15 默沙东公司 增强肺炎链球菌多糖-蛋白缀合物的免疫原性
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
CN110996992A (zh) * 2017-08-16 2020-04-10 默沙东公司 肺炎球菌缀合物疫苗制剂
CN116898959A (zh) 2017-09-07 2023-10-20 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
EP3678652A4 (en) 2017-09-07 2021-05-19 Merck Sharp & Dohme Corp. ANTIPNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN POLYSACCHARIDE-CARRIER PROTEIN IMMUNOGENIC CONJUGATES
KR102573200B1 (ko) 2017-12-06 2023-08-31 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질접합체를 포함하는 조성물 및 그의 사용 방법
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
CN112074293A (zh) 2018-04-30 2020-12-11 默沙东公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
KR102120830B1 (ko) * 2018-09-20 2020-06-09 고려대학교산학협력단 신규 b군 연쇄상구균 혈청형 균주 및 이를 포함하는 면역원성 조성물
PE20211888A1 (es) 2018-12-19 2021-09-22 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y sus metodos de uso
CA3139257A1 (en) * 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
CN112741901B (zh) * 2019-10-31 2024-05-10 北京科兴中维生物技术有限公司 一种含有5型肺炎链球菌荚膜多糖的疫苗及其制备方法
JP2023503086A (ja) 2019-11-22 2023-01-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細菌サッカリド複合糖質ワクチンの用法及び用量
WO2021250628A1 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Bacterial immunization using nanoparticle vaccine
WO2021250625A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Gbs ferritin nanoparticles
CN114073761B (zh) * 2020-08-11 2023-11-14 山东大学 一种寡糖缀合物及其作为预防v型b族链球菌感染糖疫苗的应用
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN112939164B (zh) * 2021-03-15 2022-05-24 广西大学 海产养殖水体的消毒方法
US20220387576A1 (en) * 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN113480622A (zh) * 2021-08-05 2021-10-08 江苏坤力生物制药有限责任公司 一种重组肺炎球菌溶血素制备及纯化的方法
CN113651730A (zh) * 2021-08-20 2021-11-16 宿迁盛瑞新材料有限公司 一种双（十八烷基）羟胺的制备方法
CN115960962A (zh) * 2021-10-09 2023-04-14 江苏金斯瑞蓬勃生物科技有限公司 一种用于加强慢病毒载体稳定性的保护剂及其用途
CN113621089B (zh) * 2021-10-11 2021-12-17 山东洁壹选生物科技有限公司 一种海藻多糖提取物的制备方法和应用
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
CN114015622A (zh) * 2021-12-14 2022-02-08 塔里木大学 无乳链球菌培养基及其制备方法

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
EP0911036A3 (en) 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IL107103A (en) * 1992-09-24 2001-03-19 Brigham & Womens Hospital A multi-valued vaccine based on an attached molecule containing a capsular polysaccharide attached to a protein and a method for preparing this special molecule
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
DE122009000058I1 (de) 1993-09-22 2009-12-31 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
ATE241384T1 (de) 1995-03-22 2003-06-15 Jackson H M Found Military Med Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DK1051506T4 (da) * 1997-12-23 2019-10-21 Pfizer Ireland Pharmaceuticals Fremgangsmåder til ekstraktion og isolering af bakterielle kapselpolysaccharider til anvendelse som vacciner eller bundet til proteiner som konjugatvacciner
US20010051364A1 (en) * 1997-12-23 2001-12-13 Francis Michon Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
SI1296713T1 (en) 2000-06-08 2004-02-29 Intercell Biomedizinische Forschungs- Immunostimulatory oligodeoxynucleotides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
MXPA03011135A (es) 2001-06-07 2004-09-08 Wyeth Corp Formas mutantes de holotoxina de colera como adyuvante.
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
TWI313609B (en) 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
DE602004017864D1 (de) * 2003-06-23 2009-01-02 Baxter Int Trägerproteine für impfstoffe
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0411387D0 (en) * 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3466982B1 (en) 2005-04-08 2020-06-17 Wyeth LLC Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation
EP1868645B1 (en) * 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0522303D0 (en) 2005-11-01 2005-12-07 Chiron Srl Culture method
NO345368B1 (no) 2005-12-22 2021-01-04 Glaxosmithkline Biologicals Sa Streptococcus pneumoniae immunogen sammensetning for anvendelse ved behandling eller forebygging av sykdommer forårsaket av Streptococcus pneumoniae infeksjon ved serotype 19A-stammer.
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
RU2460539C2 (ru) 2006-10-10 2012-09-10 Вайет СПОСОБ ОЧИСТКИ ПОЛИСАХАРИДОВ Streptococcus pneumoniae 3 ТИПА (ВАРИАНТЫ)
EP2129693B1 (en) 2007-03-23 2016-12-07 Wyeth LLC Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
CN101784282B (zh) * 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 包含肺炎链球菌荚膜多糖缀合物的疫苗
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
KR101760451B1 (ko) 2009-03-05 2017-07-24 인터디지탈 패튼 홀딩스, 인크 Ｈ(ｅ)ＮＢ 무결성 검증 및 확인을 위한 방법 및 장치
CN102625713A (zh) * 2009-06-22 2012-08-01 惠氏有限责任公司 用于制备金黄色葡萄球菌血清型5和8荚膜多糖缀合物免疫原性组合物的组合物和方法
WO2011080570A2 (en) 2009-12-29 2011-07-07 Micro Labs Limited Extended release pharmaceutical composition comprising linezolid and process for preparing the same
JP2013538211A (ja) * 2010-08-23 2013-10-10 セレクタ バイオサイエンシーズ インコーポレーテッド 抗原に対する免疫反応を誘発する標的マルチエピトープ剤形
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US9120848B2 (en) 2010-09-23 2015-09-01 Harvey Kaplan Non-aqueous synthesis of polysaccharide-protein conjugates for vaccines
WO2012061400A2 (en) 2010-11-01 2012-05-10 University Of Maryland, Baltimore Method for reduction of free polysaccharide in polysaccharide-protein vaccines reactions using ion-exchange matrices
GB201121301D0 (en) * 2011-12-12 2012-01-25 Novartis Ag Method
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
MX363511B (es) * 2012-08-16 2019-03-26 Pfizer Proceso de glucoconjugación y composiciones.
BR112015005081B1 (pt) 2012-09-07 2021-10-26 Sk Bioscience Co., Ltd. Método para produzir um polissacarídeo capsular tendo um sorotipo de pneumococo
EA201590427A1 (ru) 2012-10-02 2015-09-30 Глаксосмитклайн Байолоджикалс С.А. Нелинейные сахаридные конъюгаты
RU2015106791A (ru) * 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA2943263C (en) * 2012-12-20 2018-12-04 Pfizer Inc. Glycoconjugation process
US10563193B2 (en) * 2013-12-02 2020-02-18 Brandeis University Multivalent glycopeptides that tightly bind to target proteins
EP3607966A1 (en) * 2014-01-21 2020-02-12 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
RU2743793C1 (ru) * 2014-01-21 2021-02-26 Пфайзер Инк. Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты
EP3443983B1 (en) * 2014-02-14 2022-07-20 Pfizer Inc. Immunogenic glycoprotein conjugates
US10150979B2 (en) * 2014-05-07 2018-12-11 Glaxosmithkline Biologicals Sa Purification of secreted polysaccharides from S. agalactiae
TWI583284B (zh) * 2015-02-06 2017-05-11 鴻海精密工業股份有限公司 保護殼
PE20180172A1 (es) * 2015-05-04 2018-01-22 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
MY187461A (en) 2015-06-08 2021-09-23 Serum Inst Of India Private Ltd Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
CN109789198A (zh) 2016-09-30 2019-05-21 生物E有限公司 包含多糖-蛋白缀合物的多价肺炎球菌疫苗组合物
US10751402B2 (en) * 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
KR102565771B1 (ko) * 2017-05-05 2023-08-10 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 박테리아 협막 폴리사카라이드 기반 제제로부터의 불순물의 제거 방법

Also Published As

Publication number Publication date
TW201704254A (zh) 2017-02-01
EP3292146A1 (en) 2018-03-14
PH12017501898A1 (en) 2018-03-05
CN107624070A (zh) 2018-01-23
RU2692923C2 (ru) 2019-06-28
RU2017136859A (ru) 2019-06-04
CA2928602A1 (en) 2016-11-04
CN114010775A (zh) 2022-02-08
NZ736238A (en) 2022-07-01
CO2017011245A2 (es) 2018-03-28
US20210145957A1 (en) 2021-05-20
WO2016178123A1 (en) 2016-11-10
US10226525B2 (en) 2019-03-12
PE20180172A1 (es) 2018-01-22
TW202135856A (zh) 2021-10-01
US10946086B2 (en) 2021-03-16
KR20190128264A (ko) 2019-11-15
AU2016258284B2 (en) 2019-01-17
KR102143534B1 (ko) 2020-08-12
IL255106A0 (en) 2017-12-31
IL255106B2 (en) 2023-04-01
JP6948951B2 (ja) 2021-10-13
AU2019202680A1 (en) 2019-05-09
JP2018514571A (ja) 2018-06-07
AU2016258284A1 (en) 2017-11-02
IL255106B (en) 2022-12-01
SG11201708242YA (en) 2017-11-29
PE20220774A1 (es) 2022-05-16
IL297740A (en) 2022-12-01
TWI718144B (zh) 2021-02-11
KR102045663B1 (ko) 2019-11-15
AU2019202680B2 (en) 2020-05-14
TWI807252B (zh) 2023-07-01
ZA201807203B (en) 2022-05-25
MY182282A (en) 2021-01-18
AU2016258284C1 (en) 2020-09-03
US20190142922A1 (en) 2019-05-16
SA517390274B1 (ar) 2022-12-22
MX2017014127A (es) 2018-03-01
US20230346903A1 (en) 2023-11-02
SG10202101887WA (en) 2021-03-30
KR20170138568A (ko) 2017-12-15
BR112017022776A2 (pt) 2018-07-10
US20160324950A1 (en) 2016-11-10
RU2017136859A3 (es) 2019-06-04
JP2024009978A (ja) 2024-01-23
JP2022008445A (ja) 2022-01-13

Similar Documents

Publication Publication Date Title
PH12017501898A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
PH12019500672A1 (en) Multivalent pneumococcal vaccine compositions comprising polysachharide-protein conjugates
PH12021550318A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2021015775A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos.
JOP20200141A1 (ar) تركيبات مشتملة على متقارنات بروتين عديد سكاريد المكورات العقدية الرئوية وطرق استخدامها
BR112020004396A8 (pt) Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
GB201101665D0 (en) Immunogenic compositions
FI3583947T3 (fi) Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit
MX2019005423A (es) Conjugado proteico de polisacarido inmunogenico que comprende un polisacarido derivado de estreptococo grupo b (gbs).
BR112020004509A8 (pt) Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
NO20083722L (no) Immunogen sammensetning
BR112018007812A2 (pt) polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica.
CR20210333A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
MX2021014948A (es) Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae.
WO2015051371A3 (en) Haemophilus parasuis vaccine serovar type four
MX2021015155A (es) Polisacaridos de ramnosa.
AR104514A1 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
MX349930B (es) Composiciones inmunogenas.
WO2019157188A3 (en) Compositions and methods for cross-protection against pneumococcal disease
JO3420B1 (ar) تركيبة صيدلانية ولقاح للوقاية من اصابات المكورة العقدية

Legal Events

Date Code Title Description
FG Grant or registration